US psychiatric medication prescribing faces reduction drive for children
Updated
Updated · The Wall Street Journal · May 10
US psychiatric medication prescribing faces reduction drive for children
12 articles · Updated · The Wall Street Journal · May 10
Health Secretary Robert F. Kennedy Jr. said the HHS plan adds reimbursement for tapering patients off drugs, a Dear Colleague letter, and a technical panel to draft summer guidelines.
The initiative targets overprescribing and long-term side effects in young people, amid high diagnosis and medication rates including about 44 million US adults on antidepressants.
Supporters see a response to a mental-health crisis, while critics argue insurance and reimbursement rules encourage overdiagnosis, prescribing cascades and medication over therapy or lifestyle changes.
Can new guidelines curb overprescribing when the healthcare system financially rewards more diagnoses?
What are the true long-term costs of medicating an entire generation of young minds?
Are we medicating a genuine mental health crisis or simply pathologizing the struggles of modern life?
The MAHA Action Plan 2026: Federal Overhaul of Psychiatric Prescribing for Children and Foster Youth
Overview
The MAHA Action Plan, launched by the U.S. Department of Health and Human Services in May 2026, is a comprehensive federal mandate to improve mental health care. Its main goal is to re-establish gold-standard scientific practices, ensuring that children and adults receive accurate information to make well-informed treatment decisions and access needed support. The plan focuses on addressing psychiatric medication prescribing for children by promoting appropriate prescribing and deprescribing, and by strengthening holistic, evidence-based care models. Through new guidelines and clinician training, the MAHA Action Plan aims to create safer, more individualized, and transparent mental health care for all.